Literature DB >> 21476889

Disease-related death in patients who were considered free of macroscopic disease after initial treatment of well-differentiated thyroid carcinoma.

Iain J Nixon1, Ian Ganly, Frank L Palmer, Monica M Whitcher, Snehal G Patel, R Michael Tuttle, Ashok R Shaha, Jatin P Shah.   

Abstract

BACKGROUND: Death from well-differentiated thyroid cancer (WDTC) is rare, and over the past century there has been a trend away from local recurrence as the primary cause of death. The objective of our study was to report the cause of death from thyroid cancer in patients with WDTC treated with curative intent with surgery ± adjuvant radioactive iodine.
METHODS: An institutional database of 1811 patients with WDTC treated surgically for WDTC between 1986 and 2005 was analyzed and identified 165 (9.4%) who had died. Case records were studied to determine the cause of death in each patient.
RESULTS: Of the 165 deaths, 17 (10%) patients were confirmed to have died of thyroid cancer and 6 (4%) died of an unknown cause but had thyroid cancer present at the time of last follow-up. The remaining 142 (86%) died from other causes and were considered free of thyroid cancer at their last follow-up. We therefore identified only 23 cause-specific deaths from the entire cohort (1.3%). Of the 17 patients known to have died of thyroid cancer, all had distant recurrence. Ninety-four percent had pulmonary metastases. Of these, 47% also had bony metastasis at the time of death. Two patients had recurrent disease in the neck at the time of death, but both also had distant disease. Of the six patients (4%) who died of unknown causes but had thyroid cancer at last follow-up, four (67%) had distant disease alone, one (17%) had local and regional recurrence, and one had local and distant recurrence at last follow-up.
CONCLUSION: After successful resection of WDTC, we report a low disease-specific death rate (1.3%). In contrast to earlier reports, death caused by central compartment disease in this recent series is very rare, with metastatic disease accounting for almost all fatalities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21476889     DOI: 10.1089/thy.2010.0451

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  5 in total

Review 1.  Management of Invasive Differentiated Thyroid Cancer.

Authors:  Iain J Nixon; Ricard Simo; Kate Newbold; Alessandra Rinaldo; Carlos Suarez; Luiz P Kowalski; Carl Silver; Jatin P Shah; Alfio Ferlito
Journal:  Thyroid       Date:  2016-08-23       Impact factor: 6.568

2.  Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF network.

Authors:  Françoise Bonichon; Thierry de Baere; Amandine Berdelou; Sophie Leboulleux; Anne-Laure Giraudet; Marie Cuinet; Delphine Drui; Renan Liberge; Antony Kelly; Florence Tenenbaum; Paul Legmann; Christine Do Cao; Laurence Leenhardt; Michel Toubeau; Yann Godbert; Jean Palussière
Journal:  Endocrine       Date:  2021-03-26       Impact factor: 3.633

3.  Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?

Authors:  Dauren Adilbay; Avery Yuan; Paul B Romesser; Richard J Wong; Jatin P Shah; Ashok R Shaha; Michael R Tuttle; Snehal Patel; Nancy Y Lee; Ian Ganly
Journal:  Ann Surg Oncol       Date:  2022-05-18       Impact factor: 4.339

4.  Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer.

Authors:  Tom Edward Ngo Lo; Abigail Uy Canto; Patricia Deanna D Maningat
Journal:  Endocrinol Metab (Seoul)       Date:  2015-10-20

5.  Risk stratification in differentiated thyroid cancer with RAI-avid lung metastases.

Authors:  Keiko Ohkuwa; Kiminori Sugino; Mitsuji Nagahama; Wataru Kitagawa; Kenichi Matsuzu; Akifumi Suzuki; Chisato Tomoda; Kiyomi Hames; Junko Akaishi; Chie Masaki; Koichi Ito
Journal:  Endocr Connect       Date:  2021-07-26       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.